rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Cell Culture Engineering
  name:
    name part: Hu, Wei-Shou.
    role:
      role term: editor.
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: gw
    date issued: 2006
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: XI, 168 p. online resource.
  abstract: Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.
  table of contents: Established Bioprocesses for Producing Antibodies as a Basis for Future Planning -- Fedbatch Culture and Dynamic Nutrient Feeding -- The “Push-to-Low” Approach for Optimization of High-Density Perfusion Cultures of Animal Cells -- Towards Industrial Application of Quasi Real-Time Metabolic Flux Analysis for Mammalian Cell Culture -- Engineering Cells for Cell Culture Bioprocessing – Physiological Fundamentals.
  note: edited by Wei-Shou Hu.
  subject:
    topic: Chemistry
  subject:
    topic: Biotechnology
  subject:
    topic: Biochemistry
  subject:
    topic: Cell biology
  subject:
    topic: Chemistry
  subject:
    topic: Biotechnology
  subject:
    topic: Cell Biology
  subject:
    topic: Biochemistry, general
  classification: TP248.13-248.65
  classification: 660.6
  related item:
    title info:
      title: Springer eBooks
  related item:
    title info:
      title: Advances in Biochemical Engineering/Biotechnology, 101
  identifier: 9783540340072
  identifier: http://dx.doi.org/10.1007/11751571
  record info:
    record creation date: 100301
    record change date: 20151110141250.0
    record identifier: 978-3-540-34007-2